Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $12K rose 50.0% year over year, ahead of the +47.0% change in trailing-twelve-month income tax expense. Sequentially, it fell 90.8% from the prior quarter. Over 3 fiscal years it compounded at +80.6% a year.

Context

  • Income tax expense amounted to 279.7% of revenue in FY2025, up 253.8 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +50.0% holds above the trailing-twelve-month pace of +47.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12K-90.8% QoQ
Last fiscal yearDec 2025
$165K+44.7% YoY
LTMMar 2026
$169K+47.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.0%——
1 year+44.7%——
3-year CAGR+80.6%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
165K USD
Year-over-year change
+44.7%

Income Tax Expense vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +47.0% is the 6th highest of 8, against a peer median of +100.0%.
  • Income tax expense amounts to 286.4% of revenue for AVTX, versus a peer median of 0.0%.
AVTX Competitors
Income Tax Expense for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$2.48M USD+53.2%+55.0%2.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$169K USD+47.0%+80.6%286.4%
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$35K USD-91.9%——
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€4K EUR+100.6%——
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
QTTBQ32 Bio Inc.LTM Mar 2026$0 USD-100.0%—0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —+100.0%+72.4%0.0%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.